|
|
 Previous Article | Table of Contents | Next Article 
Recombinant human interleukin-11 stimulates multilineage hematopoietic
recovery in mice after a myelosuppressive regimen of sublethal irradiation
and carboplatin
JP Leonard, CM Quinto, MK Kozitza, TY Neben and SJ Goldman
Genetics Institute, Cambridge, MA 02140.
Interleukin-11 (IL-11) is a novel multifunctional hematopoietic cytokine
capable of stimulating cells of the myeloid, lymphoid, erythroid, and
megakaryocytic lineages in vitro. We have tested the pleiotropic properties
of this cytokine on the hematopoietic recovery of mice after a combined
regimen of sublethal irradiation and carboplatin administration. This
regimen results in severe myelosuppression, characterized by a prolonged
period of thrombocytopenia and severe anemia. Administration of recombinant
human IL-11 (rhIL-11; 250 micrograms/kg/d) had multilineage effects on bone
marrow and spleen hematopoietic activity, increasing the number of
megakaryocyte, erythroid, granulocyte, and macrophage progenitors compared
with the vehicle-treated controls. This was reflected in the peripheral
circulation by a reduction of both the platelet and hematocrit nadirs and a
significantly reduced period of thrombocytopenia and anemia in the
rhIL-11-treated mice. The results from this study support the broad
spectrum of biologic activities that have been attributed to rhIL-11 in
vitro and suggest that this cytokine may be an effective agent in the
treatment of myelosuppression associated with cancer chemotherapy and bone
marrow transplantation.
Volume 83,
Issue 6,
pp. 1499-1506,
03/15/1994
Copyright © 1994 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
K. Matsumura-Takeda, S. Sogo, Y. Isakari, Y. Harada, K. Nishioka, T. Kawakami, T. Ono, and T. Taki
CD41+/CD45+ Cells Without Acetylcholinesterase Activity Are Immature and a Major Megakaryocytic Population in Murine Bone Marrow
Stem Cells,
April 1, 2007;
25(4):
862 - 870.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. J. Jenkins, A. W. Roberts, M. Najdovska, D. Grail, and M. Ernst
The threshold of gp130-dependent STAT3 signaling is critical for normal regulation of hematopoiesis
Blood,
May 1, 2005;
105(9):
3512 - 3520.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Inagaki, T. Oda, Y. Naka, H. Shinkai, N. Komatsu, and H. Iwamura
Induction of megakaryocytopoiesis and thrombocytopoiesis by JTZ-132, a novel small molecule with thrombopoietin mimetic activities
Blood,
July 1, 2004;
104(1):
58 - 64.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Drouet, F. Mourcin, N. Grenier, V. Leroux, J. Denis, J.-F. Mayol, P. Thullier, J.-J. Lataillade, and F. Herodin
Single administration of stem cell factor, FLT-3 ligand, megakaryocyte growth and development factor, and interleukin-3 in combination soon after irradiation prevents nonhuman primates from myelosuppression: long-term follow-up of hematopoiesis
Blood,
February 1, 2004;
103(3):
878 - 885.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. J. Kuter and C. G. Begley
Recombinant human thrombopoietin: basic biology and evaluation of clinical studies
Blood,
November 15, 2002;
100(10):
3457 - 3469.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. J. MacVittie, A. M. Farese, W. G. Smith, C. M. Baum, E. Burton, and J. P. McKearn
Myelopoietin, an engineered chimeric IL-3 and G-CSF receptor agonist, stimulates multilineage hematopoietic recovery in a nonhuman primate model of radiation-induced myelosuppression
Blood,
February 1, 2000;
95(3):
837 - 845.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. S. Weich, M. Fitzgerald, A. Wang, J. Calvetti, J. Yetz-Aldape, S. Neben, and K. J. Turner
Recombinant human interleukin-11 synergizes with steel factor and interleukin-3 to promote directly the early stages of murine megakaryocyte development in vitro
Blood,
January 15, 2000;
95(2):
503 - 509.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Shibuya, H. Akahori, K. Takahashi, E. Tahara, T. Kato, and H. Miyazaki
Multilineage Hematopoietic Recovery by a Single Injection of Pegylated Recombinant Human Megakaryocyte Growth and Development Factor in Myelosuppressed Mice
Blood,
January 1, 1998;
91(1):
37 - 45.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. S. Weich, A. Wang, M. Fitzgerald, T. Y. Neben, D. Donaldson, J. Giannotti, J. Yetz-Aldape, R. M. Leven, and K. J. Turner
Recombinant Human Interleukin-11 Directly Promotes Megakaryocytopoiesis In Vitro
Blood,
November 15, 1997;
90(10):
3893 - 3902.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. H. Nandurkar, L. Robb, D. Tarlinton, L. Barnett, F. Kontgen, and C. G. Begley
Adult Mice With Targeted Mutation of the Interleukin-11 Receptor (IL11Ra) Display Normal Hematopoiesis
Blood,
September 15, 1997;
90(6):
2148 - 2159.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H Akahori, K Shibuya, M Ozai, M Ida, K Kabaya, T Kato, and H Miyazaki
Effects of pegylated recombinant human megakaryocyte growth and development factor on thrombocytopenia induced by a new myelosuppressive chemotherapy regimen in mice
Stem Cells,
November 1, 1996;
14(6):
678 - 689.
[Abstract]
|
|
|
|
|
|
|
F. Schlerman, A. Bree, M. Kaviani, S. Nagle, L. Donnelly, L. Mason, R. Schaub, S. Grupp, and S. Goldman
Thrombopoietic activity of recombinant human interleukin 11 (rHuIL-11) in normal and myelosuppressed nonhuman primates
Stem Cells,
September 1, 1996;
14(5):
517 - 532.
[Abstract]
|
|
|
|
|
